The high productivity of Eucalyptus spp. forest plantations is mainly due to advances in silvicultural techniques and genetic improvement associated with the potential that many species of the genus have for vegetative propagation. However, long reproduction cycles for forest species pose significant challenges for genetic progress via traditional breeding programs. Furthermore, there is often poor correlation between individual (seedling) performance in initial (progeny trials) and final (clonal trials) stages of the breeding program. In this scenario, cloned progeny trials (CPT) offer an alternative to accelerate the eucalypt clone selection pipeline, combining progeny and clonal trials in a single experiment. CPT has the potential to speed up the evaluation process and increase its efficiency by developing new commercial genotypes that were tested as clones from the initial stage of the breeding program. Thus, this study aims to assess the potential of CPT to accelerate eucalypt clone selection programs by estimating the genetic parameters, analyzing responses to selection, and predicting the adequate number of ramets to be used in CPT of Eucalyptus urophylla x Eucalyptus grandis. The results show that when the number of ramets per progeny was decreased from five to one there was a reduction in the estimates of broad-sense heritability and accuracy. However, three ramets/progeny can be used without significant reductions in these estimates. CPT accelerates clonal selection by combining progeny and clonal trial methodologies, enabling an evaluation of performance as both progeny and clone. This capacity is very important for vegetatively propagated crop species such as Eucalyptus. Integrating CPT with SNP markers can offer an alternative to shorten the tree clone selection pipeline, better estimate and decompose the genetic variance components, and improve the correlation between initial and final performance for selected genotypes. This study confirms the potential of CPT to improve selection processes and accelerate genetic gains in the eucalypt clone selection pipeline.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827336PMC
http://dx.doi.org/10.1186/s13007-025-01342-3DOI Listing

Publication Analysis

Top Keywords

clone selection
20
eucalypt clone
16
selection pipeline
16
progeny trials
12
selection
8
cloned progeny
8
clonal trials
8
breeding program
8
offer alternative
8
accelerate eucalypt
8

Similar Publications

Stone pine (Pinus pinea L.) is an emblematic tree species within the Mediterranean basin, with high ecological and economic relevance due to the production of edible nuts. Breeding programmes to improve pine nut production started decades ago in Southern Europe but have been hindered by the near absence of polymorphisms in the species genome and the lack of suitable genomic tools.

View Article and Find Full Text PDF

In Vitro Activity of Bacteriophages Against Ocular Methicillin-resistant S. aureus Isolates Collected in the US.

Ophthalmol Ther

March 2025

Team "Staphylococcal Pathogenesis", CIRI - Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon, France.

Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of sight-threatening infections in the US. These strains pose a significant challenge in managing ocular infections, as they frequently exhibit resistance to first-line empirical antibiotics. To assess the potential of bacteriophages as innovative topical therapies for treatment of recalcitrant ocular infections, we evaluated the in vitro antimicrobial activity of a set of anti-S.

View Article and Find Full Text PDF

Functional Activity and Binding Specificity of Small Ankyrin Repeat Proteins Called Ankyrons Against SARS-CoV-2 Variants.

AAPS J

March 2025

Hemostasis Branch 1, Division of Hemostasis, Office of Plasma Protein Therapeutics, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, Maryland, 20993, USA.

Effective management of COVID-19 requires clinical tools to treat the disease in addition to preventive vaccines. Several recombinant mAbs and their cocktails have been developed to treat COVID-19 but these have limitations. Here, we evaluate small ankyrin repeat proteins called Ankyrons that were generated to bind with high affinity to the SARS-CoV-2 virus.

View Article and Find Full Text PDF

carbapenemases (KPCs) have evolved into over 245 distinct variants, with over one-third of variants exhibiting reduced susceptibility to ceftazidime-avibactam, while the underlying selection mechanisms remain elusive. To better elucidate these resistant phenotypes, we cloned 33 clinically described KPC variants (from KPC-2 to KPC-36) and 8 artificially created variants into a common plasmid vector and assessed their impact on β-lactam susceptibility. Strains expressing KPC-14, KPC-28, and KPC-31 exhibited increased resistance to ceftazidime and ceftazidime-avibactam but decreased resistance to carbapenems.

View Article and Find Full Text PDF

A growing number of novel antipseudomonal β-lactams have been introduced in recent years, but the emergence of resistance is still a major concern in the treatment of infections. Here, we compared the mutant prevention concentrations (MPCs) and the nature of first-step resistant mutants to classical and novel β-lactams in . MPCs were determined in duplicate experiments for ceftazidime, ceftazidime/avibactam, ceftolozane/tazobactam, imipenem, imipenem/relebactam, meropenem, meropenem/vaborbactam, aztreonam, aztreonam/avibactam, and cefiderocol in PAO1, PAOMS (Δ), and three extensively drug-resistant (XDR) clinical strains belonging to high-risk clones ST111, ST175, and ST235.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!